In a somewhat unexpected move, in January 2019 it was reported that CardioDX had laid off all 110 workers and close operations. This decision was made shortly after decision was made public in late 2018 by Medicare that they would no longer cover the firm's lead product: a bllod test for heart disease. CardioDx had been a biotechnology and diagnostics company specializing in cardiovascular genomic diagnostics. A molecular diagnostics company, CardioDx develops tested for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. Using clinically-validated tests that allowed clinicians better tto ailor care to each individual patient, CardioDX's prime product was the Corus CAD, a blood test which allows physicians to determine if a patients chest discomfort is due to obstructive coronary artery disease. Corus CAD is a gene expression test (not a genetic test) that examines the expression changes associated with atherosclerosis. In addition to the Corus CAD, CardioDx had been investigating other diagnostics for cardiac arrhythmia and heart failure.
